Financials

  • Market Capitalization 2.87 B
  • Employee 117
  • Founded 2002
  • CEO N/A
  • Website www.dbv-technologies.com
  • Headquarter France
  • FIGI BBG0076D3T39
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-2.64
Price to sales ratio
72.2
Dividends per share
Dividend yield %

DBV Technologies S.A. - American Depositary Shares

DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration.